WI Pharmacy Board Newsletters

GLP-1 Compounding Rules, Board Membership, Renewal Info

The Wisconsin Pharmacy Examining Board newsletter advises pharmacies dispensing compounded GLP-1 medications (such as semaglutide or tirzepatide) to ensure compliance with Wis. Admin. Code ch. Phar 15 requirements, including facility, process, documentation, and verification standards. The newsletter references FDA guidance warning that compounders may not produce drugs essentially copies of FDA-approved drugs unless documented shortages apply. The newsletter also announces the upcoming license renewal period opening April 12, 2026 and closing May 31, 2026, and notes that 2025 WI Act 167 will add two pharmacy technician seats to the Board.

Wisconsin Pharmacy Board Rule Changes

The Wisconsin Pharmacy Examining Board has updated Chapter Phar 7, concerning the Practice of Pharmacy, with changes effective January 1, 2021. These updates were adopted on June 4, 2020, and provide important information for licensees regarding pharmacy practice regulations.

Wisconsin Pharmacy Board Updates and Rule Changes

The Wisconsin Pharmacy Examining Board issued a newsletter on September 17, 2020, providing updates on rule changes, COVID-19 variances, and enforcement actions. A key update concerns changes to administrative rules in Chapter Phar 7, effective January 1, 2021.

Wisconsin Pharmacy Board Rule Updates and Enforcement Actions

The Wisconsin Pharmacy Examining Board has updated administrative rules effective August 1, 2020, affecting rule chapters Phar 6 (Storage) and Phar 17 (Internships). These updates include adoption orders outlining specific changes to storage requirements and internship regulations for licensed pharmacists and interns in Wisconsin.

Wisconsin Pharmacy Board Activities: PDMP, HOPE, Opioid Treatment

The Wisconsin Pharmacy Board is providing an update on its activities, including the implementation of the Prescription Drug Monitoring Program (PDMP), participation in the Heroin, Opiate Prevention and Education (HOPE) legislation, and significant rewrites of Chapters 7 (Pharmacy Practice) and 15 (Sterile Pharmaceuticals) of its rules. The PDMP has seen substantial provider registration and inquiry volume, aiming to curb controlled substance abuse.